Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12819945 | 0.84 | RAB9A (0.53) | HPGDLMNAPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL12818254 | 0.84 | RAB9A (0.53) | HPGDLMNAPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL15262428 | 0.84 | RAB9A (0.46) | HPGDLMNAPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL1710059 | 0.83 | RAB9A (0.68) | HPGDLMNAPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL15985671 | 0.83 | GRM5 (0.47) | HPGDLMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6363488 | 0.80 | ALDH1A1 (0.58) | HPGDLMNAPOLBSMN1; SMN2MAPT | |
| SCHEMBL30880540 | 0.80 | HPGD (0.49) | HPGDLMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4973001 | 0.80 | HPGD (0.49) | HPGDLMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL12819942 | 0.80 | SMN1; SMN2 (0.51) | HPGDLMNAPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL12819385 | 0.80 | SMN1; SMN2 (0.51) | HPGDLMNAPOLBRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793530-B2 | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793530-B2 | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR65, GPR52 | HPGD 1635/4885LMNA 3079/4885POLB 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.